Revolution Medicines, Inc. D&A increased by 3.5% to $2.35M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 38.7%, from $1.69M to $2.35M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 26.0% CAGR.
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $803.00K | $793.00K | $816.00K | $901.00K | $931.00K | $1.00M | $1.14M | $1.21M | $1.20M | $1.30M | $1.34M | $1.54M | $1.60M | $1.60M | $1.82M | $1.69M | $1.76M | $2.06M | $2.27M | $2.35M |
| QoQ Change | — | -1.2% | +2.9% | +10.4% | +3.3% | +7.4% | +14.0% | +5.7% | -0.4% | +8.3% | +2.8% | +15.2% | +3.9% | +0.0% | +13.7% | -7.0% | +3.9% | +17.3% | +9.9% | +3.5% |
| YoY Change | — | — | — | — | +15.9% | +26.1% | +39.7% | +33.7% | +28.9% | +30.0% | +17.3% | +27.8% | +33.3% | +23.1% | +36.1% | +9.9% | +9.9% | +28.9% | +24.6% | +38.7% |